The primary outcome for both SCA3 and MSA-C was the difference between the active and placebo groups in the proportion of patients with an improvement of 1.5 points in SARA score after 2 weeks of treatment. This evidence concerns the gene ATXN3 and multiple system atrophy, cerebellar type.